Trial Profile
Pivotal phase IIb/III trial of low-dose naltrexone for Crohn's disease
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Naltrexone (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Biostax
- 26 Mar 2018 According to an Immune Therapeutics media release, IMUN/Cytocom expects to submit final protocols for this pivotal rollover trial based on the meeting with the FDA shortly
- 26 Mar 2018 According to an Immune Therapeutics media release, the company will also filing with the FDA an Investigational New Drug (IND) application to Lodonal in pediatric patients age 2 to 11 in the treatment of mild to severe Crohns disease.
- 26 Mar 2018 According to an Immune Therapeutics media release, the company announced that it has received minutes from the Type C meeting held on January 16, 2018, between Immune Therapeutics on behalf of Cytocom, the license holder, and the US Food and Drug Administration (FDA).